Key facts
- BIXINK Therapeutics’s last known valuation is $9.2M (Feb 2025).
- It has raised $4.2M; the latest was Later Stage VC ($4.2M) in Feb 2025.
- Notable investors include Korea Investment Partners, G.N. Tech Venture Capital, KEPCO Plant Service & Engineering.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for BIXINK Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for BIXINK Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BIXINK Therapeutics
Developer of cancer therapy designed to create a new treatment paradigm. The company is engaged in developing digital therapeutics for health treatment, enabling professionals to treat patients.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2016
- Employees
- 16
- Website
- bixink.com/
- Ownership
- Privately Held (backing)
BIXINK Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BIXINK Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BIXINK Therapeutics in its N-PORT filings yet. We sweep new filings monthly.